Immune cell therapy takes on stubborn stomach bug in transplant patients
NCT ID NCT04691622
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether specially grown immune cells (norovirus-specific T-cells) can safely treat chronic norovirus infections in people with weakened immune systems, such as those who had a stem cell or organ transplant. The study will enroll 48 participants and give them one of three doses of these cells. The main goal is to check for side effects, not yet to see if the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
norovirus-specific T-cells (NST therapy)
What this could lead to
If it works, this could point toward a treatment for chronic norovirus in people with weakened immune systems, helping clear the infection.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (48 people) and may not work or could cause side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Institutes of Health (NIH)
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact